Nephrology Stents and Catheters Market Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2028

Nephrology Stents and Catheters: Market Insights

Nephrology stents and catheters are one of the key products and treatment option in nephology for drainage of obstructed urine in patients. Blockage in of one or both the ureters leads to usage of nephrostomy stents and catheters. Nephrology stents and catheters are generally inserted under medication of local anesthetic, which helps in temporal diversion of urine form blockade. Insertion of nephrostomy stents and catheters requires well-trained and qualified personnel. These nephrostomy procedures can also be a primary treatment option where antibiotics become ineffective. The most common usage of nephrology stents and catheters are in the patients suffering from cancer of reproductive organs. Other indications for usage of nephrology stents and catheters include UTI infections, benign prostate hyperplasia, urinary incontinence and others.

Nephrology Stents and Catheters: Market Dynamics

Over the years, increase incidence of kidney stone has been the primary market growth driver for nephrology stents and catheters market. Additionally, increasing incidence of various cancers in ovary, bladders and prostate etc. have increased the demand for usage of nephrology stents and catheters. Many reports have also reported that there is an increase in post-operative infection in kidney transplant patients and this has resulted in high demand for nephrostomy devices such as nephrology stents and catheters. However, stenting and catheterization challenges in percutaneous nephrostomy over the years have hindered the growth of global nephrology stents and catheters market.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-9133

Nephrology Stents and Catheters Market: Segmentation

Segmentation Based on Product Type

• Nephrology Catheters
  • Balloon Catheters
  • Malécot Catheters
  • J Tip Catheters
  • Pigtail Catheters
• Nephrology Stents
• Metal Stents
• Plastic Stents

Segmentation by End User Type:

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

Nephrology Stents and Catheters Market: Overview

The global market for nephrology stents and catheters is highly fragmented due to presence of local and global players. It is anticipated that major players will account for the largest share in the global nephrology stents and catheters market. Some of the new techniques and lunch of balloon dilation catheters having multilayer technology will help in driving the nephrology stents and catheters market. Amongst two category of nephrology products, catheters segment are anticipated to generate the maximum revenue in nephrology stents and catheters market.

Nephrology Stents and Catheters Market: Region-wise Outlook

Geographically, North America is anticipated to be leading region in terms of revenue in nephrology stents and catheters market followed by Europe. Increase incidence of ovarian, bladder and prostate cancer in both the regions are anticipated fuel the demand for usage of nephrology stents and catheters. In some of the growing economies of East Asia, South Asia and Latin America and South America, cancer awareness and their treatment will also drive nephrology stents and catheters market. However, lack of trained personnel in nephrology catheterization and stenting procedures in some regions of Africa and Middle East may adversely affect the market growth in the forecast period.

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-9133

Nephrology Stents and Catheters Market: Key Players

The comprehensive market research report provides analysis of key manufacturers having significance presence in the market and their strategies which they follow to sustain the competitive environment of the nephrology stents and catheters market. The report also offers information about various research and developmental activities of these players that focus on to come up with innovative solutions. Some of the key and major players operating in global nephrology stents and catheters market include, Angiodynamics, Inc., Rocamed, Ameco Medical Industries, Boston Scientific Corporation, UROMED, Teleflex Incorporated, Cardinal Health Inc., C. R. Bard, Inc. Envaste Limited, Merit Medical Systems and  Medi-globe Corporation . In addition presence of small and local manufacturers across the countries will account for competiveness in nephrology stents and catheters market.

Neglected Tropical Disease Treatment Market 2018 Revenue, Opportunity, Forecast and Value Chain 2028

Neglected tropical disease treatment offers a great chance of survival for patients mainly belong to the poorest of the poor society, Neglected tropical disease treatment forms a group because all such conditions are strongly associated with poverty, impoverished environments, and majorly conditions mainly thrive in tropical regions. There are rare conditions that can only be seen in tropical regions and also require innovative disease management, conditions like Buruli ulcer, leishmaniasis, Chagas disease, and African sleeping sickness require concerned treatment procedure.

Neglected Tropical Disease Treatment Market: Drivers and Restraints

The scenario has changed over the years with major healthcare and governing bodies offering prime support to such patients, expanding the neglected tropical disease treatment to a greater extent. WHO has been a major role player in the movement, by leading pharmaceutical companies to donate billions worth drugs for neglected tropical disease treatment. Today, the neglected tropical diseases have their centers in the places with poor socioeconomic progress as compare to the rest of the world. Though, neglected tropical disease treatments has led to less no of such reported cases, but a great number of unreported cases mark a greater potential for the neglected tropical disease treatment market. Basically, driving points for neglected tropical disease treatment market are the technological differences made over the years and period evolution which is not accepting the deaths of people struck by neglected tropical disease. For a long time, the only neglected tropical disease treatment options were unsafe and hurting. As, neglected tropical disease treatment required expert care, including stays in hospitals, and diagnostic serives which was more often not available in such conditions, lack of sanitations and good resources led to the disease in first place. But the situations is changing with advent of new advanced treatment tools and responses for neglected tropical disease treatment. Since all this takes place as a global initiative, targeted for eradicating conditions which are not accepted in on a global level. The neglected tropical disease treatment market is hence dependent on the donation and funding collected with resourceful helping authorities.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-9132 

Neglected Tropical Disease Treatment Market: Segmentation

Tentatively, the global Neglected Tropical Disease Treatment market has been segmented on the basis of Drug Class, Disease Type, Distribution Channel and Geography.

Based on Drug Class, the global Neglected Tropical Disease Treatment market is segmented as

• Anti-Parasite
• Antifungal
• Antibiotics
• Others

Based on Disease Type, the global Neglected Tropical Disease Treatment market is segmented as:

• Leishmaniasis
• Schistosomiasis
• Lymphatic Filariasis
• Chagas Disease
• African Trypanosomiasis
• Others

Based on Distribution Channel, the global Neglected Tropical Disease Treatment market is segmented as:

• Direct Sales
• Indirect Sales

Neglected Tropical Disease Treatment Market: Overview

The global market for Neglected Tropical Disease Treatment is growing with increase in awareness and healthcare progression. With a majority of neglected tropical disease treatment offered in tropical region of Latin America, Africa and parts of Asia. Though, neglected tropical disease treatment market is segmented into three, disease type, drug class and distribution channel. Most of the drug used for neglected tropical disease treatment is anti-parasitic. As the diseases are often related to parasitic relations which require care and treatment. The sales of such drugs in such condition are often carried by governing bodies like WHO, indirect sales of these drugs is more present with proper set regulation for the required use. Neglected tropical disease treatment market would experience an expansion during the forecast period in relation with the required care and rising awareness towards health issues in devolving regions.

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-9132

Neglected Tropical Disease Treatment Market: Regional Wise Outlook

Geographically, the neglected tropical disease treatment market is segmented into eight regions viz. North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East and Africa. The Latin America neglected tropical disease treatment market is estimated to account a considerable market value share in the global neglected tropical disease treatment market. Economical, physical and government factors influence the Latin America neglected tropical disease treatment market. MEA region has its own considerable share in the neglected tropical disease treatment and the region is expected to expand with treatment getting into small spaces of its geography. A rising growth is valued over the region for neglected tropical disease treatment market.

Major player involved in this market for Neglected Tropical Disease Treatment are F. Hoffmann-La Roche Ltd., Abbott, ZeptoMetrix, Genome Diagnostics Pvt. Ltd. Omega Diagnostics Group PLC, Oscar Medicare Pvt Ltd. and Thermo Fisher Scientific, Inc. These are few companies present in the neglected tropical disease treatment market with projections of new market players in future.

Mast Cell Tumors Treatment Market Trends and Forecast 2018 - 2028: Pfizer Inc.,Bausch Health Companies Inc.

Mast cell tumor (Mastocytoma) is formed by aggregation of number of mast cells to form big cist like structure. It is a type of rare disease usually seen in infants aged from 0 to 3 months and rarely diagnosed in adults. Mast cells are associated with the histamine release and which causes allergic reactions when secreted in excess. Accumulation of extra mast cells generally appears in single to three lesions on body trunk or wrist. Activation of these extra mast cells results in excessive release of histamine and various different chemicals causing localized redness, swelling and itching. Increasing awareness about rare diseases resulting in improved diagnostic rate subsequently followed by increasing mast cell tumors treatment rate. Various manufacturers in the mast cell tumors treatment market are trying to develop novel treatment option by investing in mast cell tumors treatment research & development. Mast cell tumors (mastocytoma) is subtype of the cutaneous mastocytosis affecting approximately 10% to 30% of all cases. Although epidemiology of mast cell tumor is not clear but numerous controlled studies are being carried out to evaluate the actual epidemiology of the disease in different parts of the world. After the WHO updated the classification, diagnosis, and treatment approach, various countries implemented the same guidelines to improve uniformity in the diagnostic and treatment approach.

Mast Cell Tumors Treatment Market: Drivers and Restraints

Increasing data availability around disease expected to improve the treatment approach in turn driving the growth of the mast cell tumors treatment market. Increasing awareness about mast cell tumors treatment option through social media platforms, advocacy groups, various government and non-government organizations expected to improve treatment seeking rate, driving the growth of mast cell tumors treatment market. Improving diagnosis rate followed by increased mast cell tumors treatment seeking rate expected to fuel the growth of the market. Extended efforts by the manufacturers to develop novel mast cell tumors treatment due to various benefits offered by regulatory authorities under orphan drug status further expected to fuel the growth of the mast cell tumors treatment market. Whereas, patient to patient varying symptoms makes mast cell tumors treatment difficult, which may hamper the potential growth of the mast cell tumors treatment market.

Request Sample Report @  https://www.futuremarketinsights.com/reports/sample/rep-gb-9131

Mast Cell Tumors Treatment Market: Segmentation

The global mast cell tumors treatment market is segmented based on the by drug class, route of administration, distribution channel and region

By drug class, mast cell tumors treatment market is segmented as:

• Antihistamines
• Epinephrine
• Steroids
• Mast-cell stabilizers

By route of administration, mast cell tumors treatment market is segmented as:

• Oral
• Injectables
• Topical

By distribution channel, mast cell tumors treatment market is segmented as:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Mast Cell Tumors Treatment Market: Overview

Mast cell tumors treatment market is expected to experience steady growth over the forecast period attributing to increasing diagnosis rate and mast cell tumors treatment seeking rate. By drug class, antihistamine is expected to be the most lucrative segment in the global mast cell tumors treatment market. By route of administration, oral is expected to be most lucrative segment in the mast cell tumors treatment market. By distribution channel, hospital pharmacies is expected to be highest revenue generating segment in the mast cell tumors treatment market. Various pharmaceutical manufacturers are planning to evaluate different molecules for mast cell tumors treatment e.g. In November 2018, GT Biopharma received FDA clearance for the human phase study of First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550.

Mast Cell Tumors Treatment Market: Regional Outlook

The global mast cell tumors treatment market is expected to be dominated by North America due to comparatively higher prevalence of the mast cell tumors in the region. Europe is expected to be second most lucrative mast cell tumors treatment market due to increasing treatment seeking rate. Asia-Pacific is emerging mast cell tumors treatment market attributing to increase in diagnosis rate as well as product availability. Latin America mast cell tumors treatment market is expected to experience gradual growth whereas MEA mast cell tumors treatment market expected to be least lucrative due to low prevalence as well as low diagnosis.

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-9131

Mast Cell Tumors Treatment Market: Key Players

The key market players operating in the mast cell tumors treatment market are:, Pfizer Inc.,Bausch Health Companies Inc., Mylan NV, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Sanofi S.A., Bayer AG, Novartis AG, EPI Health, LLC, and others.

Erdheim-Chester Disease Market Outlook, Research, Trends and Forecast to 2028

Erdheim-Chester disease (ECD) is a rare disease which occurs in adults. It is identified by excessive accumulation and production of histiocytes (white blood cells) within organs and tissues. The Histocytes are basically macrophages which react to injuries and infections.  The disease occurs in both men and women. Erdheim Chester treatment can be life-threatening with complications such as severe damage to the lungs, heart failure, and kidney failure. However, with Erdheim Chester treatment, there are patients who are alive and are living a near-normal life. Majorly Erdheim Chester disease affects long bones (legs and arms) however it can also occur in tissues behind the eyeballs, skin, kidney, brain, heart, lung, and pituitary gland,  Erdheim-Chester disease treatment has not been successful. However, various Erdheim-Chester disease treatments have been used with limited success. Erdheim-Chester disease treatment includes immunotherapy (which is used to restore the capabilities of immune system), steroids, radiation therapy (usage of high-energy rays) and Chemotherapy with which over-production of cells is controlled, and surgery.

Erdheim-Chester Disease Treatment Market: Drivers and Restraints

Global Erdheim-Chester Disease has occurred to approximately 600-700 patients. As there is no accepted Erdheim-Chester Disease treatment more than half of the patients die within 3 years of treatment. Also there are involvement of other bones such as lower jaw bone and vertebrae during the course of disease. The Histiocytosis Association Research Program has been established to find the cure for Erdheim-Chester Disease which will be an advantage and lead to an effective Erdheim-Chester Disease Treatment.  The programs are providing funding for basic and clinical research. According to the histocytosis association $265,000 has been funded by Histiocytosis Association of Canada (HAC) which is expected to drive the Erdheim-Chester Disease Treatment Market. Many manufactures are ongoing research efforts for Erdheim-Chester Disease Treatment. Also A new pilot clinical trial for the treatment of Hemophagocytic lymphohistiocytosis (HLH) has opened in the U.S. which is expected to increase the Erdheim-Chester Disease Treatment. Moreover a study is expected to open soon in Europe. Continuous research and development and experiments for the Erdheim-Chester Disease Treatment are being tried which are predicted to drive the Erdheim-Chester Disease Treatment Market.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-9102

Erdheim-Chester Disease Treatment Market: Outlook

Geographically, global Erdheim-Chester Disease Treatment Market is classified into regions viz. North America, Latin America, Asia Pacific, Middle East & Africa, Eastern Europe and Western Europe. North America’s Erdheim-Chester Disease Treatment Market is growing due to the increasing research and development for rare disease Treatments. Advancement and continuous progression with continuous funding in the development of new drugs is expanding the Erdheim-Chester Disease treatment.  In developed countries such as U.S and Europe patient care is considered the top most priority. Positive government support with rising healthcare expenditure is expected to increase Erdheim-Chester Disease Treatment market. Also Developing countries such as China and India are progressively caring out healthcare reforms which will further expand the market for Erdheim-Chester Disease Treatment market.

Erdheim-Chester Disease Treatment Market: Key Players

Major market members in the Global Erdheim-Chester Disease Treatment Market  identified across the value chain include:, Aspen Pharmacare, Salix Pharmaceuticals, Zydus Pharmaceuticals, Inc. , Sandoz International GmbH, SANIS., Aphena Pharma Solutions, F. Hoffmann-La Roche Ltd, Genentech, Inc., Cardinal Health, Pfizer Inc., West-Ward Pharmaceuticals Corp., Novartis International AG, Dr. Reddy's Laboratories Ltd., Accord Healthcare, Janssen Global Services, LLC ,  and others

Erdheim-Chester Disease Treatment Market: Segmentation

Tentatively, Erdheim-Chester Disease Treatment Market has been segmented on the basis of product type, application, and end user.

On the Basis of therapies, Erdheim-Chester Disease Treatment Market can be segmented as:

• Immunotherapy
• Imuran
• Mycophenolate Mofetil
• Mycophenolate Sodium
• Chemotherapy
  • Vinblastine
  • Vincristine
  • Doxorubicin
  • Cladribine
  • Gleevec
  • Others
• Histiocytes suppression Drugs
  • Cyclophosphamide
  • Methotrexate

Request to View TOC @  https://www.futuremarketinsights.com/toc/rep-gb-9102

On the Basis of Distribution channel, Erdheim-Chester Disease Treatment Market can be segmented as:

• Hospital pharmacy
• Specialty Clinic pharmacies
• Online stores

C-Reactive Protein Analyzers Market 2018 | Global Industry Overview 2028 | Top Companies Eurolyser Diagnostica GmbH, Dr. Müller Gerätebau GmbH

C-Reactive Protein Analyzers : Market Insights

C-Reactive Protein (CRP) acts as a marker for the diagnosis of inflammation in the body. CRP is produced in the liver and is detected in the blood when there is any inflammation in the body. The various causes of the high level of CRP in the blood are chronic inflammatory diseases such as lupus or rheumatoid arthritis, cancers, heart attack etc. CRP test can detect various infections in the body such as pneumonia, skin infections etc. Apart from infections, this test can also be used to detect inflammatory bowel disease, rheumatoid arthritis etc. Tuberculosis, Burns or trauma can also lead to the presence of high level of C-reactive protein into the blood. CRP tests are also performed to monitor the effectiveness of a particular treatment for any inflammatory disease. 

There are some companies, which are focusing to innovate new products in the market. For example- In 2018, Abbott introduced “Afinion” analyzer for the diagnosis of diabetes. The Afinion analyzer measures hemoglobin and albumin to creatinine ratio.

There are certain risks, associated with the tests, such as excessive bleeding, dizziness, and infection at the puncture site, which can decrease the adoption of C-reactive protein tests.

There is a lack of public awareness, regarding this test, especially in the emerging regions such as India, which can hinder the growth of C-reactive protein analyzers market.

According to an article of 2016 in Journal of Medicine, Radiology, Pathology & Surgery, more than 50% of the population suffering from diabetes are unaware of this CRP test, for the early diagnosis of diabetes.

Request Sample Report @https://www.futuremarketinsights.com/reports/sample/rep-gb-9101

C-Reactive Protein Analyzers: Market Dynamics

An increasing prevalence of inflammatory disorders such as rheumatoid arthritis, lupus and other blood-related diseases etc. is expected to drive the C-reactive protein analyzers market. Increasing healthcare awareness is another important factor, which can increase the demand for C-reactive Protein Analyzers Market. Other factors such as the increase in the research and developmental activities, an increasing number of hospitals and diagnostic laboratories, increasing adoption of a point of care devices, technological advancement are expected to increase the growth of the C-reactive protein Analyzers Market.

Lack of diagnostic awareness is expected to restrain the growth of the C-reactive Protein Analyzers Market. C-reactive protein tests are very expensive, hence, can hinder the growth of the overall C-Reactive protein Analyzers Market. There can be some alternative tests which can replace C-reactive protein tests, reducing the demand of C-reactive protein analyzers.

C-Reactive Protein Analyzers Market: Segmentation

The C-Reactive Protein Analyzers market is segmented by indication and end user:

• Segmentation by Indication
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Lupus
• Cardiovascular Diseases
• Others
• Segmentation by End users Hospitals Diagnostic Laboratories Academic and Research Institutes

C-Reactive Protein Analyzers Market: Overview

C-Reactive Protein Analyzers are used for diagnosing rheumatoid arthritis, inflammatory bowel disease, lupus, cardiovascular diseases and other diseases such as cancer, endometriosis etc. Rheumatoid arthritis and cardiovascular diseases is expected to hold the maximum revenue share in the c-reactive protein analyzers market. Based on the end user. Diagnostic laboratories is expected to hold the maximum revenue share in the overall c-reactive protein analyzers market.

C-Reactive Protein Analyzers Market: Region-wise Outlook

On the basis of geography, global C-Reactive Protein Analyzers market has been divided into few regions. These regions include North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa. North America is projected to hold the largest shares in the global C-Reactive Protein Analyzers market due to the presence of well-established healthcare infrastructure and high technological advancement. However, Europe is expected to be the second largest to hold the revenue share in C-Reactive Protein Analyzers market because of the high incidence of inflammatory disorders and the presence of a large population.

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-9101

C-Reactive Protein Analyzers Market: Key Players

Some of the key players present in global C-Reactive Protein Analyzers market are Eurolyser Diagnostica GmbH, Dr. Müller Gerätebau GmbH, Abbott, Paramedical s.r.l., Sugentech, Inc.,biosurfit SA, Orion Diagnostica, Nano-Ditech Corp, SD Biosensor.

Late Stage Chronic Kidney Disease Therapeutics Market Report 2028: Market Trends and Competitive Analysis & Forecast

Late stage chronic kidney disease therapeutics can be defined as the drugs which are used for the treatment of late-stage CKD - Induced, Hyperphosphatemia, Hyperparathyroidism and Hyperkalemia.

The dramatic increase in CKD prevalence have maintaining the unmet need for the late stage chronic kidney disease therapeutics. In spite of the introduction of new late stage chronic kidney disease therapeutics the market is expected to have opportunity to grow. 

Late Stage Chronic Kidney Disease Therapeutics Market: Drivers and Restraints

The rise in the prevalence of CKD are the main reason for the increasing demand of late stage chronic kidney disease therapeutics. As per to CDC, 15% of the US adults are suffering from CKD and 48% of the CKD patients are not aware of the condition or not on dialysis.

On the other hand the introduction of new late stage chronic kidney disease therapeutics such as calcimimetic and new HK agents is expected to drive the growth of the late stage chronic kidney disease therapeutics market in the forecast period.

Favourable reimbursement policy for the late stage chronic kidney disease therapeutics and rising awareness among patients and practitioner for the consequences of CKD is also fuelling the market of late stage chronic kidney disease therapeutics.

In the saturated market of late stage chronic kidney disease therapeutics, the new entrants will face problem to establish their presence in the late stage chronic kidney disease therapeutics market. Although agreements and partnerships between dialysis centers and manufacturers will remain a key strategy to maintain dominance in late stage chronic kidney disease therapeutics market.

Request Sample Report @https://www.futuremarketinsights.com/reports/sample/rep-gb-9195

Late Stage Chronic Kidney Disease Therapeutics Market: Segmentation

To gain a comprehensive and a better understanding of the future late stage chronic kidney disease therapeutics market equity, the market report is segmented based on product type, clinical practice, indication end user and region.

Based on the product type late stage chronic kidney disease therapeutics is segmented into:

• Calcimimetics
• Sensipar (cinacalcet hydrochloride)
• Vitamin D SterolsNutritional/Native Vitamin DVitamin D Receptor Agonists
• Phosphate BindersCalcium-Based Phosphate BindersAluminum-Containing Phosphate BindersMagnesium-Containing Phosphate BindersRenvela/RenagelFosrenol (lanthanum carbonate)Velphoro (sucroferric oxyhydroxide)Auryxia (ferric citrate)
• Potassium BindersResinsVeltassa (patiromer sorbitex calcium)

On the basis of indication, Late Stage Chronic Kidney Disease Therapeutics Market can be segmented as:

• Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
• Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
• Late Stage Chronic Kidney Disease Induced Hyperkalemia

On the basis of end users, late stage chronic kidney disease therapeutics market can be segmented as:

• Hospital Pharmacy
• Retail Pharmacy
• Mail Order Pharmacy

On the basis of geography, late stage chronic kidney disease therapeutics market can be segmented as:

• North America
• Latin America
• Europe
• Middle East & Africa (MEA)
• South Asia
• East Asia
• Oceania

Late Stage Chronic Kidney Disease Therapeutics Market: Overview

Global late stage chronic kidney disease therapeutics market has witnessed growth due to rising prevalence of chronic kidney diseases. The introduction of new therapies and favorable reimbursement scenario for the late stage chronic kidney disease therapeutics also propel the growth of the market

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-9195

Late Stage Chronic Kidney Disease Therapeutics Market: Region-wise Outlook

Geography wise, late stage chronic kidney disease therapeutics market is divided into seven regions viz. North America, Latin America, Europe, Middle East & Africa (MEA), South Asia, East Asia and Oceania. Favorable reimbursement and rising prevalence of CKD in the North American region is expected influence the market and therefore the North America late stage chronic kidney disease therapeutics market will remain dominant in the forecast period.

Late Stage Chronic Kidney Disease Therapeutics Market: Key Market Participants

Some of the market participants in the global late stage chronic kidney disease therapeutics market identified across the value chain include: AbbVie, Amgen, Ardelyx, AstraZeneca, Deltanoid, Genzyme, Keryx, Kyowa Hakko Kirin, Mitsubishi Tanabe, OPKO Health, Relypsa, Sanofi, Shield Therapeutics, Shire, Spectrum, Vifor and ZS Pharma

Homecare Dermatology Energy-based Devices Market Outlook and Opportunities in Grooming Regions 2028

Shift from Clinics to Home-based Energy Treatments

The growing awareness among general population regarding the benefits of homecare dermatology energy-based devices and technological advancement are increasing their adoption across the globe. These homecare dermatology energy-based devices save money and time and are easy to buy as they are available over the counter. These are some of the factors contributing to the growth of the homecare dermatology energy-based devices market.

Increasing Burden of Skin Disorders

Rising prevalence of skin problems has been leading to scarring. Acne and wrinkles are considered the most common skin problems in the U.S., which are affecting over 50 million people yearly. Majority of physical changes, including permanent scarring occur due to acne. Moreover, about 85% of people aged between 12 and 24 experience acne. The commonly used homecare dermatology energy-based devices for the treatment of acne and wrinkles are LEDs. Thus, rising prevalence of skin disorders is directly expected to drive the growth of the global homecare dermatology energy-based device market over the forecast period. 

Increasing Use of Technology Combinations in Products

LEDs are used for reducing fine lines, bringing of skin tone, while lasers are target specific and effective. The combination of both the devices can lead to better results. Also, increasing use of combination of technologies have better outcomes. LED lights have anti-bacterial properties which stop the growth of acne. Also, majority of the treatments work on all the skin tones. For instance, RF Beaute Photo PLUS works on a combination of radio frequency and LED technology. LED minimises the apparence of wrinkles and fine lines and reduces the pore size while the RF removes the dirt from skin.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7699

New Product Launches Governed by Regulatory Approvals in the Homecare Dermatology Energy-based Devices Market

Product launches in the homecare dermatology energy-based device market are specifically governed by certain regulations, whose approval is necessary for the launch of products in the market. Over the last few years, leading players in homecare dermatology energy-based device market have received regulatory approvals across major geographic markets, which have enabled them to launch various products in the market. For instance, in October 2017, Home Skinovations Inc. received FDA clearance for its Anti-Aging Device Titan, which is proven to tighten the skin and enhance beauty without undergoing invasive procedures.

Adverse Effects of Treatment with Homecare Dermatology Energy-based Devices

A wide range of side effects are linked with homecare dermatology energy-based devices, as these treatments work differently on different skin tones. It becomes difficult to determine suitability for hair removal treatments. The consumers can risk themselves to burns and pigmentation while treating an area that is not suitable. Also, there is a variation in the energy levels in home based lasers and IPL devices, which occurs due to the degradation of the components inside the device and can adversely affect the skin.

Competitive Landscape

This section of the report features profiles of the key players operating in the homecare dermatology energy-based devices market based on their market shares, product offerings, differential strategies, company dashboard and marketing approach. Examples of some of the key players featured in the report on the homecare dermatology energy-based device market include Shenzhen Leaflife Technology Co., Ltd., Dezac group ( Rio Beauty), Norlanya Technology Co., Home Skinovations Inc., Koninklijke Philips,  Johnson & Johnson Consumer Inc., Procter & Gamble, Tria Beauty and Conair Corporation. The companies offers a wide range of homecare dermatology energy-based devices for applications such as wrinkle reduction, hair removal, acne control and others. The key manufacturers of homecare dermatology energy-based devices are focusing on new marketing strategies to increase their product penetration and geographical presence in the global homecare dermatology energy-based devices market.

Definition

Laser equipment used at homecare are devices that are widely used for removal of hair, acne, wrinkles, skin pigmentations and others. Intense pulse light devices employ a range of light wavelengths. The equipment work on the principle of selective photothermolysis, thus these devices can be used for a broad range of targets. The LED equipment are used as a painless treatment for applications such as premature aging, acne, inflammation, hyper-pigmentation, and others. Radio frequency devices affect the deep layers of the skin, and heat stimulates the structural changes resulting in reduction of wrinkles, reduced lines and strengthening of elastic fibers.

About the Report

The company conducted a research study on the homecare dermatology energy-based devices market for the forecast period 2018 to 2028. The report offers a comprehensive evaluation of the business opportunities prevailing in the homecare dermatology energy-based devices market along with insights on the homecare dermatology energy-based devices consumer adoption process, iceberg analysis, pricing impact analysis, competition blueprint, and list of distributors for homecare dermatology energy-based devices market. The report explains the macroeconomic factors that are influencing the dynamics of the homecare dermatology energy-based devices market and its futuristic potential.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-7699

Segmentation

The report offers a comprehensive taxonomy of homecare dermatology energy-based devices market based on product type, application, distribution channel and region. The homecare dermatology energy-based devices are used for various applications such as skin rejuvenation, skin pigmentation, acne control, wrinkle reduction, and hair removal, among others. The major distributors of homecare dermatology energy-based devices are super market& hyper markets, retail pharmacies, drug stores and e-commerce. By product type, the global homecare dermatology energy-based devices market is segmented into intense pulsed light (IPL) devices, laser devices, and LED devices, radiofrequency devices and infrared devices. Based on application, the global homecare dermatology energy-based devices market is segmented into hair removal, acne, wrinkles, skin rejuvenation and pigmentation. Based on distribution channel, the global homecare dermatology energy-based devices market is segmented into super market& hyper market, retail pharmacies, drug store and e-commerce. The homecare dermatology energy-based devices market has been analyzed across regions of North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding China & Japan (APEC), China and Middle East & Africa (MEA).

Tattoo Removal Lasers Market 2018 : Detailed Analysis of Segment, Major Companies, Strategies, CAGR Status, Growth and Forecast 2028

Growing Penetration of Laser Technologies to Push Tattoo Removal Lasers Market Growth

Growing awareness among people about tattoo removal lasers, ease of treatment with new tattoo removal lasers, faster recovery, less post-operative pain, and lesser side effects as compared to surgeries are few of the factors contributing to the rise in demand for laser technology over other options available for tattoo removal. Various advantages of laser treatment for tattoo removal have led to patients switching to these treatments over surgeries. This has resulted in an increase in the number of laser procedures, particularly among other aesthetic procedures over the years.

According to The American Society for Aesthetic Plastic Surgery, in the US, a total of 52,675 procedures of tattoo removal were recorded in 2016, compared to 46,514 procedures in 2015. Thus, the number of patients opting for tattoo removal lasers has increased consistently, and has become the standard treatment for tattoo removal, which is further expected to push market growth for tattoo removal lasers.

‘Tattoo Regret’ Boosting the Demand for Innovative Tattoo Removal Technologies

With growing acceptance and ubiquity of tattooing across society, the popularity of tattoo removal lasers is also expected to grow. Approximately 30% of the population in the U.S. have at least one tattoo; approximately half of all millennials have one. However, according to a poll conducted in the US, around 25% of the population with a tattoo regret having had a tattoo made. New technologies for tattoo removal lasers allow the process to be shortened and completed with less blistering and scarring.

According to a research conducted by the NewHope Laser Skin Care Center, Picosecond tattoo removal lasers, which is one of the new technologies that is slowly being commercialized, cleared tattoos more efficiently and in less time than nanosecond technology lasers. Yellow, red, and orange pigments were observed to provide the best response to the picosecond laser of 532 nm, with 75-100% tattoo clearance post average of 2 treatments, in a majority of the cases. 7 tattoos that had black ink also responded more efficiently post 1 or 2 treatments with 1064 nm and 755 nm picosecond tattoo removal lasers.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2013

Various new technologies are being tested, used, and commercialized in the tattoo removal lasers landscape. With developments for tattoo removal lasers, there are new laser-susceptible inks for tattoos that are also being developed. These specific inks are made by combining different biocompatible pigments, further being encapsulated in polymethylmethacrylate beads. These beads are diversified when exposed to lasers, which leads to the absorption of these tattoo inks by the skin, and thus, leads to potential complete removal of the tattoo in a single session. Constant technological advancements for tattoo removal lasers are further expected to boost the demand for tattoo removal lasers.

High Laser Therapy Cost Continues to Obstruct Market Growth

Tattoo removal lasers are linked with high costs of treatment as well as devices, which further makes them unaffordable to people who fall under the low-middle income group. Tattoo removal lasers also require multiple sessions for reaching the desired result, which results into very high overall treatment cost.

According to Astanza Laser, a company that manufactures tattoo removal lasers, the average revenue per patient for an entire tattoo removal procedure is US$ 1,400. Different colors of tattoos require different wavelengths. For instance, blue and purple laser light might be unable to penetrate deep enough inside the dermis for reaching the corresponding pigment particles. Also, the choice of the color of laser beam is limited to commercially available tattoo removal lasers.

More advancements and variety of tattoos to be removed require high capital costs for tattoo removal lasers. Treatment cost also depends upon the laser used, colour, and size of the tattoo. Therefore, high treatment costs of tattoo removal are expected to hinder market growth for tattoo removal lases during the forecast period.

Stringent Regulations for Safe Tattoo Removal Treatment

One of the major concerns related to tattoo removal procedures is the safety of these procedures. The growing number of people opting for tattoo removal is a result of improved government policies and regulations related to tattoo removal procedures. According to Mehmet Kosoglu, the application reviewer for commercializing clearances of laser devices for tattoo removal, from the US FDA, the most effective and safe treatment for tattoo removal is through laser therapy, specifically performed by a dermatologist who is experienced and well-equipped with tattoo removal lasers.

Competitive Landscape: Global Tattoo Removal Lasers Market

The competition section of the tattoo removal lasers market report features the profiles of key players operating in the tattoo removal lasers market based on their differential strategies, market shares, product offerings, company dashboard, and marketing approach. Examples of some of the key players operating in the tattoo removal lasers market are Shanghai Fosun Pharmaceutical?Group?Co., Ltd.(Alma Lasers), Hologic Inc. (Cynosure), Syneron ® Medical Ltd, Lumenis, LUTRONIC , Cutera, Lynton Lasers, Fotona d.o.o. , and El.En. S.p.A. (Asclepion Laser Technologies GmbH).

Definition

Tattoo removal lasers are considered to be the gold standard for tattoo removal treatment. Tattoo removal lasers are based on the selective photothermolysis theory, which is also referred to as SPTL. This involves a mechanism for shattering tattoo particles with the use of a photomechanical effect. The energy gets absorbed by particles of the ink in a very less span of time, mostly nanoseconds.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-2013

About the Report

FMI conducted a research study on the tattoo removal lasers market for the forecast period 2018 to 2028. The report offers a comprehensive evaluation of the business opportunities prevailing in the tattoo removal lasers market, along with insights on the tattoo removal lasers market volume analysis base by region, market trends, average revenue per patient, pricing analysis based on product type, and market competition. The tattoo removal lasers market report elaborates on the macro-economic factors influencing the dynamics of the market, and its futuristic potential.

Tattoo Removal Lasers Market: Segmentation

The report on the tattoo removal lasers market offers a comprehensive taxonomy of the tattoo removal lasers market based on product type, end use, and region. The tattoo removal lasers market, by product type, is segmented into Q-switched tattoo removal lasers, picosecond tattoo removal lasers, and combination tattoo removal lasers. Q-switched tattoo removal lasers are further sub-segmented into Q-switched Nd:YAG, ruby, and alexandrite tattoo removal lasers. By end use, the tattoo removal lasers market is segmented into aesthetic clinics and tattoo studios. The tattoo removal lasers market has been analyzed across the regions of Europe, Latin America, North America, East Asia, Oceania, South Asia, and MEA (Middle East & Africa).

Weight Loss and Obesity Management Market Shows Expected Trend, Growth And Revenue with Leading Market Players

Obesity management is an evolving industry, which has been witnessing an upsurge in demand, due to the increasing medical tourism in countries such as Thailand, India, Singapore, and Malaysia. Medical tourism is a growing sector for many middle-income countries as packages for countries such as India and Thailand cost low and constitute insurance coverage. The US and the UK have been the largest source countries for medical tourism to India for weight loss and obesity management.

According to research analysis, India was one of the most affordable medical tourism destinations as the country offers a wide variety of medical procedures at a low cost. Rising medical tourism for weight loss and obesity management in such countries provide immense opportunities for the weight loss and obesity management market players to launch products and increase geographical presence in emerging markets which would further contribute in driving the growth of the global weight loss and obesity management market.

New Product Launches for Weight Loss and Obesity Management Continue to Extend the Drug Pipeline

Various big pharmaceutical companies are developing novel anti-obesity drugs for weight loss and obesity management. Companies such as Sanofi, Novo Nordisk, AstraZeneca, Boehringer Ingelheim and others are expected to launch new drugs in the weight loss and obesity management market by 2026.

The current weight loss and obesity management market is rather sparse, comprising only few FDA approved drugs in the US and other markets. More recently, the FDA has approved four new drugs since 2012. Obesity is now the most investigated indication by the number of clinical trials. The obesity drugs pipeline consists of 94 trials across all stages of clinical development.  

Request Sample Report @  https://www.futuremarketinsights.com/reports/sample/rep-gb-411

Emergence of New Technologies and Therapies Assisting Market Growth

A number of electrical stimulation systems are being used for bariatric surgeries, which help in controlling hunger by electrically stimulating the nerves that control our hunger signals. One such recently approved system by the FDA is vBloc, which stimulates the vagus nerve to control hunger so that person feels full for some time. These devices can also be used to treat other diseases along with weight loss and obesity management.

Obesity has become a major concern worldwide as diet and exercise are inadequate for weight loss and obesity management. Sometimes targeted treatments must be combined with additional pharmacologic therapy drugs such as Contrave (naltrexone and bupropion), Empatic (bupropion and zonisamide) and Qsymia (phentermine and topiramate). Regulatory agencies worldwide have shown significant interest in combination treatments through recent approvals of multiple combinations. These approvals pave way for combination approaches of obesity treatment, which are expected to revolutionize the weight loss and obesity management market globally.

Side Effects of Drugs and Other Risks Associated with Weight Loss Surgeries to Prevail

It has been proven that bariatric surgery is more effective in terms of cost and treatment than other pharmaceutical interventions for weight loss and obesity management. However, this proven effectiveness is typically associated with certain risks that cannot be understated. Some of the major risks associated are excessive bleeding, infections, blood clots, low blood sugar, and malnutrition.

For instance, the contrave drug can cause serious side effects and eruption of suicidal thoughts in patients. Though the number of weight loss and obesity drug users is rapidly increasing, studies show that there are certain side effects and adverse health effects of these drugs over the long term. The side effects of drugs and risks associated with surgeries may hamper the growth of the weight loss and obesity management market during the forecast period.

Government Initiatives May Support Efforts to Tackle Obesity

A government serves numerous vital functions in a national public health crisis, including the childhood obesity epidemic. It provides leadership by responding to prevalent obesity as an urgent public health priority and coordinating the public and private sector response.

Some of the programmes initiated for weight loss and obesity management are Just Say Yes to Fruits and Vegetables Project (JSY), Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), Eat Well Play Hard in Child Care Settings (EWPHCCS), Breastfeeding Friendly Child Care, Breastfeeding Friendly Practices Designation, Alaska Obesity Prevention & Control Program and others.

Despite government policy responses and greater individual responsibility, global obesity levels look set to keep rising. Government regulations and taxes might increase awareness of weight loss and obesity management and put pressure on food and beverage companies to reduce the calorific value of their products.

Competitive Landscape Analysis

The competition section of the weight loss and obesity management market report features profiles of key players operating in the weight loss and obesity management market based on their weight loss and obesity management market share, product offerings, and differential product marketing strategies.

A few key players featured in the weight loss and obesity management market report include Novo Nordisk A/S, GlaxoSmithKline plc., F. Hoffmann-La Roche AG, Allergan Plc, Johnson & Johnson Services, Inc, Medtronic plc., Vivus Inc., Eisai Co., Ltd., ReShape Lifesciences, Inc, Obalon Therapeutics, Aspire Bariatrics, Allurion Technologies Inc., Nalpropion Pharmaceuticals, Inc., and Beijing Noble Laser Technology Co., Ltd.

Definition

The weight loss and obesity management market covers devices and drugs used for managing or reducing weight in obese and overweight patients. Rising global burden of obesity and overweight is driving the need for preventive care. The global weight loss and obesity management market is analyzed by two segments namely product type and distribution sales.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-411

About the Report

The report on the weight loss and obesity management market offers a comprehensive evaluation of the business opportunities in the weight loss and obesity management market along with insights on the weight loss and obesity management regulatory scenario for medical devices and drugs, pipeline assessment of drugs for weight loss and obesity management, potential of anti-obesity drugs in the market, pricing analysis, entry strategies, white space analysis, and list of key manufacturers in the weight loss and obesity management market for the duration from 2018 to 2026.

Segmentation

The report offers a comprehensive taxonomy of the weight loss and obesity management market on the basis of product type, distribution sales, and region. On the basis of product type, the global weight loss and obesity management market has been segmented into drugs and devices. On the basis of distribution sales, the global weight loss and obesity management market has been segmented into institutional sales and retail sales. From a geographical perspective, the weight loss and obesity management market has been segmented into North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa (MEA), and emerging countries like China, Brazil, and India.

Antibiotic Susceptibility Testing Market 2018-2028 | Key Challenges, Competitive Landscape and Demographic Analysis

Growing use of antibiotics in treating even the most common health conditions remains a strong factor boosting demand for antibiotic susceptibility testing (AST). Increasing government funds for microbial and antibiotic susceptibility testing research and consistently improving outcome of PPPs in terms of enhanced screening and evaluation of antibiotics are playing a pivotal role in strengthening the performance of antibiotic susceptibility testing market. CDC’s ‘AMR Challenge’ involving bioMérieux is a recently announced as objective to accelerate research efforts in the field of microbial resistance.

A recently published research intelligence on the global antibiotic susceptibility testing market by Future Market Insights tracks the top five influencers pushing demand and revenue growth of the market at a global level. 

• Infectious diseases, prevailing at a high pace
• Increasing rate and tenure of hospitalization
• Growing significance of early diagnostics
• Soaring research interests in microbial susceptibility testing
• Improving funding scenario for research, driven by governments & private bodies

Request Sample Report @https://www.futuremarketinsights.com/reports/sample/rep-gb-8574 

Towards 2019, global revenue through total installed base of antibiotic susceptibility testing systems is likely to see 6.4% yearly growth over that achieved in 2018.

Entry of Technologically Advanced AST Systems to Favor Market Growth

As indicated by research, the sales of antibiotic susceptibility testing equipment will witness healthy growth owing to increasing demand for specific susceptibility testing systems to define the scope of targeted therapy. Targeting key pathogens is imperative to design a highly specific plan of treatment for a particular patient, and antibiotic susceptibility testing systems efficiently allow researchers to achieve it within a significantly short timeline.

With FDA approving a considerable number of antibiotic and microbial susceptibility testing equipment, especially in the recent past, FMI forecasts an impressive installed base for antibiotic susceptibility testing systems in coming years. Advanced technology enabled antibiotic susceptibility testing equipment allows early diagnosis that in turn improves chances of developing targeted therapy earlier. One such recent advancement enjoying visibly growing traction in market includes oCelloScope. This antibiotic susceptibility testing equipment by BioSense Solutions is an optical susceptibility screening system with the capability to deliver real-time, time-lapse imaging of multiple microbial combinations, simultaneously.

Recently, Thermo Fisher Scientific, Inc. and Becton, Dickinson and Company received FDA approvals for their new launches in antibiotic susceptibility testing space. Moreover, FDA passed an approval to a susceptibility testing device by bioMérieux that has an expanded capability to identify a particular pathogen.

Research in Screening of High Pathogen Concentration Samples to Propel Demand for AST

The process of spotting a specific set of genes responsible for antibiotic resistance is highly complicated when it comes to handling the complexities associated with samples that have high concentration of pathogens. Some of the highly desirable antibiotic susceptibility testing systems that allow direct-from-sample pathogen identification through high pathogen concentration samples, are thus likely to gain high traction in coming years.

Growing research efforts in the recognition of the presence of a specific set of antibiotic resistant genes can direct efforts for identification and selection of narrow-spectrum antibiotics, which remains among the most prominent factors pushing installed base of such antibiotic susceptibility testing equipment. A few recent launches in this segment include Genmark Diagnostics’ ePLEX Blood Culture ID Panel, Biomerieux’s BioFire FilmArray, and Luminex Corp.’s Verigene Bloodstream Infection Panel.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-8574

The report also sheds light on the increasing role of Ecommerce in the market by boosting the availability of antibiotic susceptibility testing systems. Offering improved access to susceptibility testing devices by industry’s leading brands, online retail operators have been attracting prominent vendors in the global antibiotic susceptibility testing market. A number of vendors dealing in antibiotic susceptibility testing equipment are opting for devices that are available online owing to the significantly reduced costs and additional discounts on price.

Radiation-Induced Myelosuppression Treatment Market Outlook 2018 Sales Revenue, Strategy to 2028

Top 3 Leading Manufacturers Account for Majority of the Revenue of the Radiation-Induced Myelosuppression Treatment Market

The radiation-induced myelosuppression treatment market is dominated by the top 3 manufacturers, i.e., Amgen Inc., Janssen Pharmaceutical NV and Teva Pharmaceutical Industries Ltd., who are competing on the basis of new drug approvals and geographical presence. The manufacturers of radiation-induced myelosuppression treatment are focusing on the expansion of their product portfolios by launching different products in various regions.

Amgen Inc. holds a significant revenue share in the global radiation-induced myelosuppression treatment market. Amgen Inc. also holds patents for various formulations, and is recently facing high competition from the new biosimilars that have been introduced in the radiation-induced myelosuppression treatment market from other manufacturers such as Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical NV, Sandoz, Pfizer Inc., Mylan NV and others. Through collaborations and partnerships with regional players, the manufacturers of radiation-induced myelosuppression treatment market are focusing on expanding their regional product footprint by launching new and innovative products.

Rapidly Increasing Incidence of Cancer and Decreasing Mortality Rate is Expected to Fuel Growth of the Radiation-Induced Myelosuppression Treatment Market

Although the incidence of cancer is increasing rapidly, the death rate due to cancer has decreased from 1991 to 2015, which is, in turn, contributing to revenue generation in the radiation-induced myelosuppression treatment market. According to SEER Cancer statistics, the overall death rate due to cancer in the U.S. fell by 26.0% during 1991 – 2015, which can be majorly attributed to early diagnosis and the availability of advanced treatment options such as radiotherapy, chemotherapy & surgical procedures. The early diagnosis of cancer has boosted the treatment-seeking rate in developed countries, which is a major driver of the radiation-induced myelosuppression treatment market. The radiation-induced myelosuppression treatment also holds significant potential for revenue generation in developing countries owing to improved healthcare infrastructure.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8116

Patent Expiry of Various Originator Formulations in the Radiation-Induced Myelosuppression Treatment Market

The expiry of the patents of various biologics formulations in the radiation-induced myelosuppression treatment market provides opportunities for other manufacturers in the radiation-induced myelosuppression treatment market to launch biosimilars. Majority of the patents in the radiation-induced myelosuppression treatment market were held by Amgen Inc. However, they have expired in the past five years, i.e. from 2013 to 2018, which has subsequently led to the launch and approval of various biosimilars in the high revenue-generating markets such as North America and Europe. For example, the patent for Amegen Inc.’s Neulasta, a biologic used for the treatment of neutropenia, expired in 2015 in the U.S., following which Sandoz launched Zarxio, the first biosimilar in the U.S. Although the cost variation between originator formulations and biosimilars is only 15% to 20%, it can reduce the economic burden on patients. This is driving the radiation-induced myelosuppression treatment market due to the increasing adoption of biosimilars in radiation-induced myelosuppression treatment.

Improved Efficacy with Iron Therapy along with Erythropoietin-Stimulating Agents is Positively Impacting the Radiation-Induced Myelosuppression Treatment Market

The need for blood transfusion is high in radiation-induced anemia as compared to chemotherapy-induced anemia, due to which erythropoietin-stimulating agents are used alone for radiation-induced myelosuppression treatment. Whereas, the usage of iron therapy along with Erythropoietin-Stimulating Agents (ESA) in radiation-induced myelosuppression treatment significantly lowers the need for blood transfusion. The IV iron therapy coupled with ESA helps bring the RBC count back to the normal level as compared to treatment with ESA alone. As per a study carried out by Auerbach et al., the response rate of ESA alone was 62–73% after being used for 2 to 3 weeks, whereas the response rate for treatment with ESA coupled with iron therapy was 77–86%. This significant change in the response rate will help improve efficacy and therapeutic outcomes as well as patient compliance, thus generating higher revenue in the radiation-induced myelosuppression treatment market.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-8116

Competitive Landscape

This section of the report features the profiles of the key players operating in the radiation-induced myelosuppression treatment market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. Examples of some of the key players featured in this report include Amgen Inc., Janssen Pharmaceutical NV, Teva Pharmaceutical Industries Ltd., Mylan NV, Novartis AG, Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc. and others.

The key manufacturers of radiation-induced myelosuppression treatment are focusing on increasing their geographical footprints as well as launching products to increase their revenue generation in the radiation-induced myelosuppression treatment market.

Definition

Radiation-induced myelosuppression is defined as the decreased ability of the bone marrow to produce blood cells (WBC, RBC and platelets). It occurs most commonly with cancer as an adverse effect of radiation, especially in case of cancers that are located near the bone marrow or near large bones with cavities. Radiation-induced myelosuppression can result in the decreased production of red blood cells (anaemia), white blood cells (leukopenia) and platelets (thrombocytopenia).